Trial Profile

A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vedolizumab (Primary)
Indications Crohn's disease; Ulcerative colitis
Focus Adverse reactions
Sponsors Takeda

Most Recent Events

02 Jul 2025 Planned initiation date changed from 11 Jul 2025 to 22 Oct 2025.
04 Mar 2025 Planned initiation date changed from 2 Dec 2024 to 11 Jul 2025.
14 May 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com